Crawley based company, ClinIntel Limited, has been acquired by a US based global biopharmaceutical services organisation. This development brings a truly global dimension to ClinIntel’s capabilities.
Clinintel was founded in 2008 and specialises in the provision of clinical randomization and trial supply management services. In recent years it has grown to become one of the major companies in the sector. ClinIntel’s existing expertise will now be augmented by 75 locations in 50 countries around the world.
Leading South East law firm, Thomson Snell & Passmore and Chartered Accountants McBrides Corporate Finance, worked closely together to advise the shareholders of ClinIntel throughout the transaction. Commenting on the acquisition, Joanne Gallagher, a partner in Thomson Snell & Passmore’s Corporate & Commercial team who led the TS&P legal team, said:
We are absolutely delighted to have been asked to act for the shareholders of ClinIntel in relation to this sale. This was a complex transaction which drew on a number of different areas of our corporate and commercial teams’ experience. It was essential that we worked closely with McBrides Corporate Finance to provide a seemless professional service and deliver the required result for our clients.
Nigel Kimber, lead advisor and a director at McBrides Corporate Finance who led the shareholders corporate finance team, said:
Working with Joanne and her team at TS&P we completed the deal in just 5 months. For us, this is the conclusion of a really interesting journey that began 4 years ago when McBrides became accountants to ClinIntel and has culminated with us advising them on this latest chapter in their development. It was a complex deal, partly because of the number of shareholders but also because of the interaction of US/UK accounting regulations. We are delighted it has successfully completed to the satisfaction of all parties.